Low-Sodium Xywav Leads Jazz Pharma’s Oxybate Revenues

During the second quarter, Jazz Pharmaceuticals registered a 39% year-over-year growth in net product sales of its low-sodium Xywav, reflecting its rising adoption, according to the company’s latest financial results and business highlights. More than 50% of Jazz’s oxybate revenues are now driven by Xywav, a treatment for narcolepsy and idiopathic hypersomnia (IH). The drug…

Read More